In the PARADIGM-HF (angiotensin–neprilysin inhibition versus enalapril in heart failure) trial, ischemic HF patients made up 59.9% of the angiotensin receptor–neprilysin inhibitor group vs. 60.1% of the enalapril group [67]. The gene discussed is MME; the disease is heart failure.